Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Rho(D) Immune Globulin (Human)HyperRHO® Full Dose
Medication labelWhy this: Advisory · dailymed-other
HyperRHO Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant,(13) providing the following criteria are met: The mother must be Rho(D) negative and must not already be sensitized to the Rho(D) factor. Her child must be Rho(D) positive, and should have a negative direct antiglobulin test (see PRECAUTIONS). If HyperRHO Full Dose is administered antepartum, it is essential that the mother receive another dose of HyperRHO Full Dose after delivery of an Rho(D) positive infant. If the father can be determined to be Rho(D) negative, HyperRHO Full Dose need not be given. HyperRHO Full Dose should be administered within 72 hours to all nonimmunized Rho(D) negative women who have undergone spontaneous or induced abortion, following ruptured tubal pregnancy, amniocentesis or abdominal trauma unless the blood group of the fetus or the father is known to be Rho(D) negative.(8,9) If the fetal blood group cannot be determined, one must assume that it is Rho(D) positive,(2) and HyperRHO Full Dose should be administered to the mother. HyperRHO Full Dose may be used to prevent isoimmunization in Rho(D) negative individuals who have been transfused with Rho(D) positive red blood cells or blood components containing red blood cells.(6,14)
- generic_name
- rho(d) immune globulin (human)
- product_names
- RHO(D) IMMUNE GLOBULIN (HUMAN)
- ndc
- 13533-631, 13533-631-20, 13533-631-02, 13533-631-03, 13533-631-11
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en